313 research outputs found
Marked efficacy of Rituximab in multifocal motor neuropathy associated with chronic lymphocytic leukemia
The authors describe a patient who presented a multifocal motor neuropathy (MMN) associated with a high anti-ganglioside antibody (anti-GM1 and anti-GD1) titer at the clinical onset of a B-cell chronic lymphocytic leukemia (B-CLL). Immunomodulation (IVIg plus cyclosporine) resulted in a neurological improvement and reduced anti-ganglioside antibody titers, both of which remained stable for at least six years. After this period, the patient had a severe relapse of the neuropathy, which was independent of the clinical course of the B-CLL. Both IVIg and cyclophosphamide were ineffective, and the patient became tetraplegic within six months; in the meantime, the patient displayed an increased antiganglioside antibody titer. Treatment with rituximab (RTX), which is designed to selectively inhibit B cell function, resulted in a dramatic, prompt and long-lasting neurological improvement as well as a reduced anti-ganglioside antibody titer. Although there are no previous reports of MMN in patients with B-CLL, the efficacy of RTX in the treatment of MMN in this patient may be considered remarkable. The expansion of B-cell clones may be a prerequisite for RTX effectiveness in MMN, and in dysimmune neuropathies in general
Marked efficacy of rituximab in multifocal motor neuropathy associated with chronic lymphocytic leukemia
The authors describe a patient who presented a multifocal motor neuropathy (MMN) associated with a
high anti-ganglioside antibody (anti-GM1 and anti-GD1) titer at the clinical onset of a B-cell chronic
lymphocytic leukemia (B-CLL). Immunomodulation (IVIg plus cyclosporine) resulted in a neurological
improvement and reduced anti-ganglioside antibody titers, both of which remained stable for at least six
years. After this period, the patient had a severe relapse of the neuropathy, which was independent of the
clinical course of the B-CLL. Both IVIg and cyclophosphamide were ineffective, and the patient became
tetraplegic within six months; in the meantime, the patient displayed an increased antiganglioside
antibody titer. Treatment with rituximab (RTX), which is designed to selectively inhibit B cell function,
resulted in a dramatic, prompt and long-lasting neurological improvement as well as a reduced antiganglioside
antibody titer. Although there are no previous reports of MMN in patients with B-CLL, the
eficacy of RTX in the treatment of MMN in this patient may be considered remarkable. The expansion of
B-cell clones may be a prerequisite for RTX effectiveness in MMN, and in dysimmune neuropathies in
general
Reazioni allergiche a farmaci nel piccolo paziente
Adverse drug reactions are an important public health issue. Maculopapular rashes are the most common cutaneous reactions to drug in children and most of them occur during beta-lactam therapies. The diagnosis is a relatively complex and subtle art. This article describes an approach to recognize and manage adverse drug reactions in children
CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: psoriasis-linked CARMA2sh mutants escape ULK2 censorship
The molecular complexes formed by specific members of the family of CARMA proteins, the CARD domain-containing adapter molecule BCL10 and MALT1 (CBM complex) represent a central hub in regulating activation of the pleiotropic transcription factor NF-κB. Recently, missense mutations in CARMA2sh have been shown to cause psoriasis in a dominant manner and with high penetrancy. Here, we demonstrate that in human keratinocytes CARMA2sh plays an essential role in the signal transduction pathway that connects pathogen-associated molecular patterns recognition to NF-κB activation. We also find that the serine/threonine kinase ULK2 binds to and phosphorylates CARMA2sh, thereby inhibiting its capacity to activate NF-κB by promoting lysosomal degradation of BCL10, which is essential for CARMA2sh-mediated NF-κB signaling. Remarkably, CARMA2sh mutants associated with psoriasis escape ULK2 inhibition. Finally, we show that a peptide blocking CARD-mediated BCL10 interactions reduces the capacity of psoriasis-linked CARMA2sh mutants to activate NF-κB. Our work elucidates a fundamental signaling mechanism operating in human keratinocytes and opens to novel potential tools for the therapeutical treatment of human skin disorders.This publication was made possible by a NPRP award (NPRP 7-1189-3-304) from the Qatar National Research Fund (a member of The Qatar Foundation)
- …